Psychiatry & Neurology Doctors in Spokane, WA Accepting Medicare
125 Psychiatry & Neurology doctors found. Showing 121 - 125
 Kayla Rose Cross, PMH-NP, ARNP Psychiatry & Neurology - Addiction Medicine Medicare: Not Enrolled in Medicare Practice Location: 104 S Freya St, Green, Ste 212, Spokane, WA 99202 Phone: 509-557-0450 |
Jennifer Kay Pary, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 322 W North River Dr, Spokane, WA 99201 Phone: 509-324-6464 |
 Timothy W Powell, MD Psychiatry & Neurology - Neurology Medicare: Accepting Medicare Assignments Practice Location: 105 W 8th Ave, Suite 318c, Spokane, WA 99204 Phone: 509-474-6650 Fax: 509-474-6646 |
Dr. Brian N Gipstein, M.D. Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 4407 S Madelia St, Spokane, WA 99223 Phone: 509-448-2692 Fax: 509-448-2692 |
Dr. Heidi Maria Heller, MD Psychiatry & Neurology - Neurology Medicare: Not Enrolled in Medicare Practice Location: 4815 N Assembly St, Spokane, WA 99205 Phone: 509-434-7611 |
News Archive
Mucosal delivery of IFNs a good strategy for COVID-19 prophylaxis post-exposure
Researchers from the UK and Germany recently reported a comprehensive characterization of the SARS-CoV-2 response of human nasal epithelial cells, revealing a response dominated by IFN-I/IIIs. Also, recombinant IFN-I/III treatment was found to efficiently block the replication of SARS-CoV-2, which suggests that mucosal delivery of IFNs may be a good strategy for prophylaxis post-exposure.
People with peripheral artery disease have lower Omega-3 Index, shows research
New research published in the March 18th edition of Lipids showed that people who have peripheral artery disease have a lower Omega-3 Index compared to those who don't have the disease.
Researchers pinpoint new approach that can treat pediatric leukemia
A Loyola University Health System study points to a promising new approach to treating an aggressive and usually fatal leukemia in babies.
Drug sellers, benefit managers poise for court-ordered price cuts
"A forthcoming rollback of benchmark drug prices - a court-approved move meant to benefit consumers - should have little effect on the bottom line for pharmacy-benefit managers or their clients, as companies have taken protective steps," the Wall Street Journal reports. Pharmacies, however, worry the 4 percent reduction in benchmark prices could result in Medicaid reductions. Benefit managers initially opposed the cut, but say they have adjusted contracts to make up for it.
Why cervical precancers disappear in some women and not in others
New research sheds light on why cervical precancers disappear in some women and not in others. Scientists at the Johns Hopkins Kimmel Cancer Center report in the July 1 issue of Clinical Cancer Research that the reason many of these lesions persist is an unlikely mix of human papilloma virus (HPV) strain and a woman's individual immune system.
› Verified 1 days ago
Internal Medicine
Family Medicine
Psychiatry & Neurology
Anesthesiology
Pediatrics
Radiology
Emergency Medicine
Surgery
Obstetrics & Gynecology
Orthopaedic Surgery